王艺瑾

副教授 医学院

王艺瑾,南方科技大学医学院副教授,博士生导师。2012 年和 2016 年分别于荷兰瓦赫宁根大学与研究中心、荷兰伊拉斯姆斯大学医学中心获得硕士和博士学位。美国伊利诺伊大学访问学者。王艺瑾在国际上较早开展戊型肝炎研究。其课题组以病毒性肝炎的转化研究为核心,通过多组学分析及筛选技术,揭示病毒-宿主相互作用、病毒激活及逃逸天然免疫机制、病毒特异性抵抗干扰素应答新机制,并基于此开发新型高效抗病毒药物。同时通过临床大队列研究,明确戊型肝炎慢性化、重症化、肝外感染的危险因素,以及在特殊人群中的预后判断。其研究方向还扩展到丙型肝炎病毒(HCV)、乙型肝炎病毒(HBV)以及非感染性肝病的发病机制研究。依托感染性疾病的研究,课题组同时开展以线粒体动态调控为主要研究对象的脓毒症多器官损伤研究。在非感染性肝病方面,课题组通过单细胞及空间转录组测序技术,揭示非酒精性脂肪肝空间免疫细胞特征,解释各种治疗手段中,患者不同预后的免疫学机制。

王艺瑾获得多个人才项目及国家级课题基金资助:入选广东省珠江人才计划,入选北京市科技新星计划,深圳市海外高层次人才B类。入选解放军总医院“3+1”创新人才建设工程新秀人才,入选解放军总医院优青培育计划;曾承担多项荷兰科技部项目及荷兰肝肠病协会课题基金,现主持国家自然科学基金 3 项, 参与国家科技重大专项等项目; 近年发表 SCI 论文 48 篇,其中以第一/通讯作者在Lancet Respiratory Medicine,Gastroenterology,Journal of Hepatology, Hepatology,EbioMedicine等知名权威期刊发表论文22篇,总影响因子450余分,他引9000余次,主编英文论著 1 本;相关成果多次被三大国际肝病年会选为口头报告并获青年学者奖。

个人简介

教育背景

2012/11–2016/09,荷兰伊拉斯姆斯大学医学中心,肝肠病学,博士

2010/09–2012/08,荷兰瓦赫宁根大学与研究中心,生物技术医学方向,硕士

2006/09–2010/07,南京医科大学,生物技术,学士

工作经历

2020/11-至今,    南方科技大学医学院,副教授

2016/09-2020/10, 解放军总医院第五医学中心,病理诊断与研究中心,副研究员

获奖情况及荣誉

2021, 深圳市海外高层次人才B类

2020,   亚太肝病学会 (APASL)授予的旅行奖

2019, 北京市科技新星

2019, 解放军总医院授予的“3+1”创新人才建设工程新秀人才

2019, 欧洲肝病学会(EASL)授予的青年学者奖

2019, 中美肝病学院,优秀报告奖

2019, 北京医学会 北京肝病年会,优秀论文奖

2018,   欧洲肝病年会(EASL)授予的青年学者奖

2018, 亚太肝病年会(APASL)授予的青年学者奖

2018, 北京医学会 北京肝病年会,优秀论文奖

2017, 荷兰肝病学会(NVGE)授予的 Veldhovenbeurs 奖

2017, 中华医学会 脂肪性肝病联合学术会议,优秀论文奖

2017, 北京医学会 北京肝病学术年会,优秀论文奖

2014, 欧洲肝病年会(EASL)授予的青年学者奖

研究领域

(1)以核苷酸合成和线粒体功能调控为主要靶点的抗病毒天然免疫应答新机制研究:鉴别干扰素激活信号调控因子及病原相关分子模式依赖的天然免疫信号分子。

(2)戊型肝炎转化研究:通过多组学分析及筛选技术,揭示病毒-宿主相互作用、病毒激活及逃逸天然免疫机制、病毒特异性抵抗干扰素应答新机制,并基于此开发新型高效抗病毒药物。同时通过临床大队列研究,明确戊型肝炎慢性化、重症化、肝外感染的危险因素,以及在特殊人群中的预后判断。

(3)基于线粒体动态的脓毒症多器官损伤机制及治疗靶点研究。

(4)非酒精性脂肪肝免疫学机制。


教学

医学研究前沿技术(研究生)

分子生物学实验方法及应用(本科)


学术成果 查看更多

  1. Zhou H#, Dai Z#, Li J, Wang J, Zhu H, Chang X, Wang Y*. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury. Metabolism. 2023; 140:155383. (Corresponding Author)
  2. Zhu H#, Dai Z#, Liu X#, Zhou H, Wang Y*. Serine/threonine kinase 3 promotes oxidative stress and mitochondrial damage in septic cardiomyopathy through inducing Kelch-like ECH-associated protein 1 phosphorylation and nuclear factor erythroid 2-related factor 2 degradation. Int J Biol Sci. 2023 (Corresponding Author)
  3. Li R#, Dai Z#, Liu X#, Wang C, Huang J, Xin T, Tong Y, Wang Y*. Interaction between dual specificity phosphatase-1 and cullin-1 attenuates alcohol-related liver disease by restoring p62-mediated mitophagy. Int J Biol Sci. 2023 (Corresponding Author)
  4. Wang C, Wang Y*. The role and mechanism of action of mitophagy in various liver diseases. Antioxid Redox Signal. 2022. (Corresponding Author)
  5. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, et al. Wang Y*, Pan Q*. Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022; 75:196-212. (Co-Corresponding Author)
  6. Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)
  7. Wang Y#, Liu S#, Liu H#, Li W#, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.
  8. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014; 146:1775-83.
  9. Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.
  10. Li P, Li Y, Wang Y*, Liu J, Lavrijsen M, Li Y, et al. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022; 8:eabj5908. (Co-corresponding Author)
  11. Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.
  12. Wang Y#*, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30.
  13. Wang Y#*, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300.
  14. Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)
  15. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.
  16. Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.
  17. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.
  18. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31. (Corresponding Author)
  19. Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.
  20. Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. Dig Liver Dis. 2020; 52:637-43. (Co-First Author)
  21. Wang J#, Huang A#, Wang Y#, Ji D, Liang Q, Zhao J, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial. Alimentary Pharmacology & Therapeutics. 2022; Accepted. (Co-First Author)
  22. Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5. (Co-First Author)
  23. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.
  24. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.
  25. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.
  26. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.
  27. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.
  28. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.
  29. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.
  30. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.
  31. Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.
  32. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.
  33. Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.
  34. Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.
  35. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.
  36. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.
  37. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.
  38. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.
  39. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.
  40. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.
  41. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.
  42. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.
  43. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.
  44. Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.

新闻动态 更多新闻

  • 王艺瑾教授团队博士生戴哲研究成果在APASL 2024上报告并获“Travel Award”奖

    2024-04-05
  • 专家论坛|王艺瑾:戊型肝炎病毒感染重症化和慢性化的机制

    2023-12-24
  • 《感染性疾病与免疫(英文)》第一届编委会第四次工作会议在成都顺利召开

    2023-12-23

加入团队

王艺瑾课题组博士后招聘启事
研究方向:
(1)以核苷酸合成和线粒体功能调控为主要靶点的抗病毒天然免疫应答新机制研究:利用CRISPR-Cas9技术,鉴别除已知TLR外的干扰素激活信号调控因子及病原相关分子模式依赖的天然免疫信号分子。
(2)戊型肝炎转化研究:通过多组学分析及筛选技术,揭示病毒-宿主相互作用、病毒激活及逃逸天然免疫机制、病毒特异性抵抗干扰素应答新机制,并基于此开发新型高效抗病毒药物。同时通过临床大队列研究,明确戊型肝炎慢性化、重症化、肝外感染的危险因素,以及在特殊人群中的预后判断。
(3)肝脏肿瘤发生、耐药免疫机制及精准诊断:通过单细胞及空间转录组测序技术,揭示肝细胞癌及胆管细胞癌空间免疫细胞特征,解释各种治疗手段中,患者不同预后的免疫学机制。
更多信息请访问课题组网页:https://faculty.sustech.edu.cn/wangyj3/
博士后任职资格:

年龄35岁以下,具备较高的学术水平和较强的科研能力的已获得博士学位的海内外优秀博士;
基础医学、生物化学、分子生物学、细胞生物学、免疫学相关专业;具备扎实的分子生物学研究基础,熟练掌握生物统计学分析方法和技巧;研究方向为病毒天然免疫、肿瘤发生机制;有大数据生物信息研究分析背景者优先,包括单细胞测序分析、CHIP-seq、RNA-seq分析等;
具有良好的英文听说读写能力,以第一作者发表过高水平SCI论文;
能够独立开展科研工作,并协助指导研究生;
善于沟通和交流、责任心强、具有团队合作精神。

博士后薪酬待遇及聘期:

博士后聘用期两年,年薪33万元起,含广东省生活补助15万元及深圳市生活补助6万元,并按深圳市有关规定参加社会保险及住房公积金。博士后福利费参照学校教职工标准发放。
 特别优秀候选人可以申请校长卓越博士后,年薪可达50万元以上。(含广东省及深圳市补助)。
 在站期间,可依托学校申请深圳市公租房,未依托学校使用深圳市公租房的博士后,可享受两年税前2800元/月的住房补贴。
 拥有优良的工作环境和境内外合作交流机会,博士后在站期间享受两年共计2.5万学术交流经费资助。
 课题组协助符合条件的博士后申请“广东省海外青年博士后引进项目”。即在世界排名前200名的高校(不含境内,排名以上一年度泰晤士、USNEWS、QS和上海交通大学的世界大学排行榜为准)获得博士学位,在广东省博士后设站单位从事博士后研究,并承诺在站2年以上的博士后,申请成功后省财政给予每名进站博士后资助60万元生活补贴(与广东省每年15万生活补助不同时享受,与深圳市每年6万元生活补助同时享受情况以深圳市规定为准);对获得本项目资助,出站后与广东省用人单位签订工作协议或劳动合同,并承诺连续在粤工作3年以上的博士后,省财政给予每人40万元住房补贴。
 博士后出站选择留深从事科研工作,且与本市企事业单位签订3年以上劳动(聘用)合同的,可以申请深圳市博士后留深来深科研资助。深圳市政府给予每人每年10万元科研资助,共资助3年(以深圳市最新申报要求为准)。
 对于符合最新《深圳市新引进人才租房和生活补贴》相关政策要求的博士后,落户深圳后,可协助申请深圳市一次性租房和生活补贴3万元(免税,自主网上申请)。
 依据自身符合的条件情况,在站或出站留深博士后可申请 "深圳市孔雀计划C类人才"或者"深圳市后备级人才",享受5年160万的奖励津贴(免税)(以深圳市最新相关人才申报要求为准)。

应聘材料:                  

个人简历;
学历证书及获奖证书扫描件;
第一作者发表的SCI论文;

请申请者将个人简历以PDF文件发送至邮箱:wangyj3@sustech.edu.cn。邮件标题注明:应聘博后+本人姓名+所学专业
 
查看更多

联系我们

联系地址

广东省深圳市南山区学苑大道1088号南方科技大学台州楼411

办公电话

电子邮箱

wangyj3@sustech.edu.cn

Copyright © 2018 All Rights Reserved.